분자 이미징 시장 : 시장 규모, 점유율, 성장률, 산업 분석 - 유형별, 용도별, 지역별 인사이트, 예측(2026-2034년)

Growth Factors of molecular imaging Market

The global molecular imaging market is witnessing consistent growth driven by rising prevalence of chronic diseases and increasing adoption of advanced diagnostic technologies. In 2025, the market was valued at USD 2.32 billion and is projected to grow to USD 2.45 billion in 2026. Over the forecast period, the market is expected to reach USD 3.92 billion by 2034, expanding at a CAGR of 6.05%. North America dominated the market with a 43.69% share in 2025, supported by high healthcare expenditure and early adoption of advanced imaging systems.

Molecular imaging enables visualization and measurement of biological processes at the cellular and molecular levels, playing a crucial role in early disease detection, diagnosis, and treatment monitoring. Technologies such as positron emission tomography (PET) and single photon emission computed tomography (SPECT) are widely used across oncology, neurology, cardiology, and orthopedics.

Market Drivers

The primary driver of the molecular imaging market is the increasing prevalence of chronic and acute disorders, including cancer, Alzheimer's disease, cardiovascular diseases, and neurological conditions. According to the National Cancer Institute, nearly 2.0 million new cancer cases were expected to be diagnosed in the U.S., significantly increasing demand for advanced diagnostic imaging.

Additionally, the growing geriatric population is contributing to higher diagnosis rates. Aging populations are more susceptible to chronic conditions, thereby boosting the utilization of molecular imaging techniques. Rising awareness about early disease detection and continuous improvements in imaging accuracy further support market growth.

Market Restraints and Challenges

Despite steady growth, the market faces challenges due to the high cost of molecular imaging equipment. PET/CT scanners can cost between USD 0.5 million and USD 5.0 million, limiting adoption, particularly in low- and middle-income countries.

Another major challenge is the emergence of a regulated market for refurbished imaging devices. Refurbished PET/CT scanners, priced significantly lower than new systems, are gaining traction in emerging economies. This price gap is restraining new equipment sales and impacting revenue growth for manufacturers.

Market Opportunities and Trends

The expanding range of medical applications for molecular imaging presents strong growth opportunities. Molecular imaging is increasingly used to assess treatment response, guide personalized medicine, and enable point-of-care testing. Faster imaging procedures and improved image quality have further enhanced clinical adoption.

A prominent trend in the market is the shift toward technologically advanced hybrid imaging systems, such as PET/CT and SPECT/CT. These systems offer superior resolution, reduced scan times, and enhanced diagnostic accuracy. Regulatory approvals and continuous innovation by leading manufacturers are accelerating the transition from conventional to hybrid imaging technologies.

Segmentation Insights

By type, Positron Emission Tomography (PET) held the largest market share, driven by rising neurological disorder prevalence and increasing installed scanner bases per million population. The SPECT segment is also expected to grow steadily due to rising R&D investments.

By application, oncology dominated the market, owing to increasing cancer diagnosis rates. Orthopedics and neurology are anticipated to grow at notable CAGRs due to rising injury rates and neurological disorders.

By end-user, diagnostic imaging centers are expected to grow rapidly, supported by patient convenience, reduced waiting times, and the growing number of independent imaging facilities.

Regional Analysis

North America generated USD 1.01 billion in revenue in 2025, driven by advanced healthcare infrastructure and favorable reimbursement policies. Europe continues to grow due to increasing installed imaging bases and government-backed research initiatives. Asia Pacific is projected to be the fastest-growing region, supported by a large patient pool, aging population, and expanding healthcare infrastructure in countries such as China, Japan, and India.

Competitive Landscape

The molecular imaging market is consolidated, with key players such as GE Healthcare, Siemens Healthineers AG, and Koninklijke Philips N.V. dominating global market share. These companies focus on innovation, product launches, and strategic collaborations to strengthen their market presence.

Conclusion

The global molecular imaging market is poised for steady growth, expanding from USD 2.32 billion in 2025 to USD 3.92 billion by 2034. Rising prevalence of chronic diseases, increasing adoption of hybrid imaging technologies, and advancements in personalized medicine are key growth drivers. While high equipment costs and refurbished device markets pose challenges, continuous innovation and expanding clinical applications will ensure sustained market expansion throughout the forecast period.

Segmentation By Type

• Positron Emission Tomography (PET)
• Single Photon Emission Computed Tomography (SPECT)
• Others

By Application

• Cardiology
• Oncology
• Orthopedics
• Gynecology
• Neurology
• Others

By End-user

• Hospitals
• Specialty Clinics
• Diagnostic Imaging Centers
• Others

By Geography

• North America (By Type, Application, End-user, and Country)
  • U.S.
  • Canada
• Europe (By Type, Application, End-user, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Type, Application, End-user, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Type, Application, End-user, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, Application, End-user, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Disorders, Key Countries/Regions, 2024/2025
• 4.2. Technological Advancements in Molecular Imaging Equipment
• 4.3. Installed Base, Key Countries/Regions, 2024/2025
• 4.4. New Product Launches, Key Players
• 4.5. Key Industry Developments - Mergers, Acquisitions & Partnerships
• 4.6. Impact of COVID-19 on the Market

5. Global Molecular Imaging Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Positron Emission Tomography (PET)
  • 5.1.2. Single-Photon Emission Computed Tomography (SPECT)
  • 5.1.3. Others
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Cardiology
  • 5.2.2. Oncology
  • 5.2.3. Orthopedics
  • 5.2.4. Gynecology
  • 5.2.5. Neurology
  • 5.2.6. Others
• 5.3. Market Analysis, Insights and Forecast - By End User
  • 5.3.1. Hospitals
  • 5.3.2. Specialty Clinics
  • 5.3.3. Diagnostic Imaging Centers
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Molecular Imaging Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Positron Emission Tomography (PET)
  • 6.1.2. Single-Photon Emission Computed Tomography (SPECT)
  • 6.1.3. Others
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Cardiology
  • 6.2.2. Oncology
  • 6.2.3. Orthopedics
  • 6.2.4. Gynecology
  • 6.2.5. Neurology
  • 6.2.6. Others
• 6.3. Market Analysis, Insights and Forecast - By End User
  • 6.3.1. Hospitals
  • 6.3.2. Specialty Clinics
  • 6.3.3. Diagnostic Imaging Centers
  • 6.3.4. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Molecular Imaging Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Positron Emission Tomography (PET)
  • 7.1.2. Single-Photon Emission Computed Tomography (SPECT)
  • 7.1.3. Others
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Cardiology
  • 7.2.2. Oncology
  • 7.2.3. Orthopedics
  • 7.2.4. Gynecology
  • 7.2.5. Neurology
  • 7.2.6. Others
• 7.3. Market Analysis, Insights and Forecast - By End User
  • 7.3.1. Hospitals
  • 7.3.2. Specialty Clinics
  • 7.3.3. Diagnostic Imaging Centers
  • 7.3.4. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia pacific Molecular Imaging Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Positron Emission Tomography (PET)
  • 8.1.2. Single-Photon Emission Computed Tomography (SPECT)
  • 8.1.3. Others
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Cardiology
  • 8.2.2. Oncology
  • 8.2.3. Orthopedics
  • 8.2.4. Gynecology
  • 8.2.5. Neurology
  • 8.2.6. Others
• 8.3. Market Analysis, Insights and Forecast - By End User
  • 8.3.1. Hospitals
  • 8.3.2. Specialty Clinics
  • 8.3.3. Diagnostic Imaging Centers
  • 8.3.4. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. Japan
  • 8.4.2. Australia
  • 8.4.3. China
  • 8.4.4. India
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Molecular Imaging Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Positron Emission Tomography (PET)
  • 9.1.2. Single-Photon Emission Computed Tomography (SPECT)
  • 9.1.3. Others
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Cardiology
  • 9.2.2. Oncology
  • 9.2.3. Orthopedics
  • 9.2.4. Gynecology
  • 9.2.5. Neurology
  • 9.2.6. Others
• 9.3. Market Analysis, Insights and Forecast - By End User
  • 9.3.1. Hospitals
  • 9.3.2. Specialty Clinics
  • 9.3.3. Diagnostic Imaging Centers
  • 9.3.4. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Molecular Imaging Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Positron Emission Tomography (PET)
  • 10.1.2. Single-Photon Emission Computed Tomography (SPECT)
  • 10.1.3. Others
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Cardiology
  • 10.2.2. Oncology
  • 10.2.3. Orthopedics
  • 10.2.4. Gynecology
  • 10.2.5. Neurology
  • 10.2.6. Others
• 10.3. Market Analysis, Insights and Forecast - By End User
  • 10.3.1. Hospitals
  • 10.3.2. Specialty Clinics
  • 10.3.3. Diagnostic Imaging Centers
  • 10.3.4. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. GE Healthcare
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Siemens Healthineers AG
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Koninklijke Philips N.V.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Shimadzu Corporation
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. CANON MEDICAL SYSTEMS CORPORATION
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Bruker
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Lantheus Holdings, Inc.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Segami Corporation
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)